|
- Infliximab - PubMed
This activity discusses the mechanism of action and clinical applications of infliximab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α)
- What is the mechanism of action of infliximab? - Drugs. com
Infliximab is called a monoclonal antibody because the definition of monoclonal antibodies is that they bind specifically to a protein – in this case, infliximab binds specifically to TNF-α
- Infliximab: The First Monoclonal Antibody in Inflammatory Disease
Infliximab, a chimeric monoclonal antibody, is designed to specifically bind to TNF-α, a dominant form of TNF in inflammatory responses Once bound, infliximab neutralizes TNF-α, preventing it from interacting with TNF receptors on cell surfaces
- Infliximab: Uses, Interactions, Mechanism of Action | DrugBank Online
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis
- Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs . . .
Subcutaneous infliximab in patients with inflammatory bowel disease may differ in effectiveness and immunogenicity compared with intravenous infliximab, potentially eliminating the need for concomitant immunomodulators
- Use of immunomodulators in combination with infliximab in Crohns . . .
The emergence, now almost three decades ago, of the human-mouse chimeric anti-TNF monoclonal antibody infliximab as the first biologic therapy in Crohn's disease has proven to be a landmark in the management of this condition
- Infliximab - Wikipedia
Infliximab was originally developed in mice as a mouse antibody Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains They are monoclonal antibodies and have identical structures and affinities to the target
- Drug Breakdown: Infliximab - Journal of Prescribing Practice
The advancing technology in the 1990s led to improved B cell cloning, immunogenicity and kinetics #infliximab was an early TNF-alpha inhibitor licensed in 1999 for Crohn's disease and later for rheumatoid arthritis (RA)
|
|
|